Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy
Trends in Pharmacological Sciences · 2024-03 · 45 (3) · 243-254
DOI: 10.1016/j.tips.2024.01.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2024-03. Verfasst von Jeffrey White und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., Oncology Research Unit, San Diego, CA 92121, USA. Hauptthemen laut MEDLINE: Lysine Acetyltransferases, Neoplasms. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Inc., Oncology Research Unit, San Diego, CA 92121, USA.
- Pfizer Inc., Oncology Research Unit, San Diego, CA 92121, USA. Electronic address: thomas.a.paul@pfizer.com.
Zitieren
APA
White, J., Derheimer, F. A., Jensen-Pergakes, K., O'Connell, S., Sharma, S., Spiegel, N., & Paul, T. A. (2024). Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy. Trends in Pharmacological Sciences, 45(3), 243-254. https://doi.org/10.1016/j.tips.2024.01.010
Vancouver
White J, Derheimer FA, Jensen-Pergakes K, O'Connell S, Sharma S, Spiegel N, et al. Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy. Trends in Pharmacological Sciences. 2024;45(3):243-254. doi:10.1016/j.tips.2024.01.010
BibTeX
@article{White2024,
author = {White, Jeffrey and Derheimer, Frederick A and Jensen-Pergakes, Kristen and O'Connell, Shawn and Sharma, Shikhar and Spiegel, Noah and Paul, Thomas A},
title = {Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy},
journal = {Trends in Pharmacological Sciences},
year = {2024},
volume = {45},
number = {3},
pages = {243--254},
doi = {10.1016/j.tips.2024.01.010}
}
EUVIMED